Euglycemic Diabetic Ketoacidosis in a Sedated Patient after Coronary Artery Bypass Grafting: A Case Report and Literature Review

Euglycemic diabetic ketoacidosis (EDKA) is a rare and serious adverse effect of sodium-glucose cotransporter 2 inhibitors (SGLT-2i). The diagnosis is challenging due to the rarity, nonspecific symptoms, and absence of the alarmingly high blood glucose levels, and thus, it could be initially missed r...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohamad S. Alabdaljabar, Khaled M. Abdullah, Ali Almasood, Syed Salman Ali, Abdullah Ashmeg
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Case Reports in Medicine
Online Access:http://dx.doi.org/10.1155/2021/2086520
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849414992254730240
author Mohamad S. Alabdaljabar
Khaled M. Abdullah
Ali Almasood
Syed Salman Ali
Abdullah Ashmeg
author_facet Mohamad S. Alabdaljabar
Khaled M. Abdullah
Ali Almasood
Syed Salman Ali
Abdullah Ashmeg
author_sort Mohamad S. Alabdaljabar
collection DOAJ
description Euglycemic diabetic ketoacidosis (EDKA) is a rare and serious adverse effect of sodium-glucose cotransporter 2 inhibitors (SGLT-2i). The diagnosis is challenging due to the rarity, nonspecific symptoms, and absence of the alarmingly high blood glucose levels, and thus, it could be initially missed resulting in delayed treatment. This is particularly important for sedated patients, as the absence of typical clinical signs and symptoms can obscure the diagnosis. We present the case of a patient with type 2 diabetes mellitus on empagliflozin who developed EDKA while sedated after coronary artery bypass grafting (CABG) despite stopping the medication 24 hours prior to surgery. We also summarize the current literature on EDKA after CABG. Physicians must be aware and maintain a high index of suspicion for the illness, especially in patients with T2DM taking SGLT-2i and undergoing a major operation such as CABG. Emergent treatment and multidisciplinary follow-up are needed to improve patient outcomes and mitigate complications. Physicians should also consider identifying the optimal time to discontinue SGLT-2i before major surgeries and possible ketone studies in such patients, especially those sedated following the surgery.
format Article
id doaj-art-6a49ae8caffa4d3e85c8057fa1091d8b
institution Kabale University
issn 1687-9635
language English
publishDate 2021-01-01
publisher Wiley
record_format Article
series Case Reports in Medicine
spelling doaj-art-6a49ae8caffa4d3e85c8057fa1091d8b2025-08-20T03:33:39ZengWileyCase Reports in Medicine1687-96352021-01-01202110.1155/2021/2086520Euglycemic Diabetic Ketoacidosis in a Sedated Patient after Coronary Artery Bypass Grafting: A Case Report and Literature ReviewMohamad S. Alabdaljabar0Khaled M. Abdullah1Ali Almasood2Syed Salman Ali3Abdullah Ashmeg4College of MedicineCollege of MedicineCardiac CenterEndocrinology DepartmentCardiac CenterEuglycemic diabetic ketoacidosis (EDKA) is a rare and serious adverse effect of sodium-glucose cotransporter 2 inhibitors (SGLT-2i). The diagnosis is challenging due to the rarity, nonspecific symptoms, and absence of the alarmingly high blood glucose levels, and thus, it could be initially missed resulting in delayed treatment. This is particularly important for sedated patients, as the absence of typical clinical signs and symptoms can obscure the diagnosis. We present the case of a patient with type 2 diabetes mellitus on empagliflozin who developed EDKA while sedated after coronary artery bypass grafting (CABG) despite stopping the medication 24 hours prior to surgery. We also summarize the current literature on EDKA after CABG. Physicians must be aware and maintain a high index of suspicion for the illness, especially in patients with T2DM taking SGLT-2i and undergoing a major operation such as CABG. Emergent treatment and multidisciplinary follow-up are needed to improve patient outcomes and mitigate complications. Physicians should also consider identifying the optimal time to discontinue SGLT-2i before major surgeries and possible ketone studies in such patients, especially those sedated following the surgery.http://dx.doi.org/10.1155/2021/2086520
spellingShingle Mohamad S. Alabdaljabar
Khaled M. Abdullah
Ali Almasood
Syed Salman Ali
Abdullah Ashmeg
Euglycemic Diabetic Ketoacidosis in a Sedated Patient after Coronary Artery Bypass Grafting: A Case Report and Literature Review
Case Reports in Medicine
title Euglycemic Diabetic Ketoacidosis in a Sedated Patient after Coronary Artery Bypass Grafting: A Case Report and Literature Review
title_full Euglycemic Diabetic Ketoacidosis in a Sedated Patient after Coronary Artery Bypass Grafting: A Case Report and Literature Review
title_fullStr Euglycemic Diabetic Ketoacidosis in a Sedated Patient after Coronary Artery Bypass Grafting: A Case Report and Literature Review
title_full_unstemmed Euglycemic Diabetic Ketoacidosis in a Sedated Patient after Coronary Artery Bypass Grafting: A Case Report and Literature Review
title_short Euglycemic Diabetic Ketoacidosis in a Sedated Patient after Coronary Artery Bypass Grafting: A Case Report and Literature Review
title_sort euglycemic diabetic ketoacidosis in a sedated patient after coronary artery bypass grafting a case report and literature review
url http://dx.doi.org/10.1155/2021/2086520
work_keys_str_mv AT mohamadsalabdaljabar euglycemicdiabeticketoacidosisinasedatedpatientaftercoronaryarterybypassgraftingacasereportandliteraturereview
AT khaledmabdullah euglycemicdiabeticketoacidosisinasedatedpatientaftercoronaryarterybypassgraftingacasereportandliteraturereview
AT alialmasood euglycemicdiabeticketoacidosisinasedatedpatientaftercoronaryarterybypassgraftingacasereportandliteraturereview
AT syedsalmanali euglycemicdiabeticketoacidosisinasedatedpatientaftercoronaryarterybypassgraftingacasereportandliteraturereview
AT abdullahashmeg euglycemicdiabeticketoacidosisinasedatedpatientaftercoronaryarterybypassgraftingacasereportandliteraturereview